文献速递免疫规划

基于甲病毒RNA复制子载体的双价胡宁与马丘波实验性疫苗

Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.
PubMed 文献 · Vaccine · 2020-02-25

胡宁病毒(JUNV)和马丘波病毒(MACV)是2018年WHO关注清单上的两种哺乳动物沙粒病毒,在 South America 流行并分别引起阿根廷出血热(AHF)和玻利维亚出血热(BHF)。Candid #1 减毒活疫苗显著降低 AHF 发病率,但不推荐用于15岁以下儿童、孕妇或其他免疫受损个体,且其在美国获批面临挑战。本研究应用基于人用委内瑞拉马脑炎疫苗(VEEV)TC-83的甲病毒RNA复制子载体技术,构建同时表达 JUNV 和 MACV 糖蛋白前体(GPC)的复制限制性病毒样颗粒载体(VLPVs),在豚鼠中安全且有免疫原性,免疫后诱导的体液应答与致死性攻击后的完全保护相关。

要点

  • JV&MV VLPVs 在豚鼠中安全且有免疫原性。
  • 免疫诱导的体液应答与 JUNV(Romero)和 MACV(Carvallo)致死性攻击后的完全保护相关。
  • Candid #1 不推荐用于15岁以下儿童、孕妇或其他免疫受损个体。

核心结论

  • JV&MV VLPVs 在豚鼠中安全且有免疫原性,免疫诱导的体液应答与致死性攻击后的完全保护相关。

研究设计与样本

  • 应用基于人用委内瑞拉马脑炎疫苗(VEEV)TC-83的甲病毒RNA复制子载体技术,构建同时表达 JUNV 和 MACV 糖蛋白前体(GPC)的复制限制性病毒样颗粒载体(VLPVs),在豚鼠中评价安全性和免疫原性。

主要发现

  • JV&MV VLPVs 在豚鼠中安全且有免疫原性。
  • 免疫后诱导的体液应答与 JUNV(Romero)和 MACV(Carvallo)致死性攻击后的完全保护相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Junin (JUNV) and Machupo (MACV), two mammalian arenaviruses placed on the 2018 WHO watch list, are prevalent in South America causing Argentine and Bolivian hemorrhagic fevers (AHF and BHF), respectively. The live attenuated JUNV vaccine, Candid #1, significantly reduced the incidence of AHF. Vaccination induces neutralizing antibody (nAb) responses which effectively target GP1 (the viral attachment glycoprotein) pocket which accepts the tyrosine residue of the cellular receptor, human transferrin receptor 1 (TfR1). In spite of close genetic relationships between JUNV and MACV, variability in the GP1 receptor binding site (e.g., MACV GP1 loop 10) results in poor MACV neutralization by Candid #1-induced nAbs. Candid #1 is not recommended for vaccination of children younger than 15 years old (a growing "at risk" group), pregnant women, or other immunocompromised individuals. Candid #1's primary reliance on limited missense mutations for attenuation, genetic heterogeneity, and potential stability concerns complicate approval of this vaccine in the US. To address these issues, we applied alphavirus RNA replicon vector technology based on the human Venezuelan equine encephalitis vaccine (VEEV) TC-83 to generate replication restricted virus-like-particles vectors (VLPVs) simultaneously expressing cellular glycoprotein precursors (GPC) of both viruses, JUNV and MACV. Resulting JV&MV VLPVs were found safe and immunogenic in guinea pigs. Immunization with VLPVs induced humoral responses which correlated with complete protection against lethal disease after challenge with pathogenic strains of JUNV (Romero) and MACV (Carvallo).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Johnson DM, Jokinen JD, Wang M, et al. Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector. Vaccine. 2020. PMID: 32111526. doi:10.1016/j.vaccine.2020.02.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。